Celyad Oncology S.A.
CYAD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 82.4% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $1 | $2 |
| Gross Profit | $0 | $0 | -$1 | -$2 |
| % Margin | 93.5% | 32.4% | – | – |
| R&D Expenses | $3 | $5 | $19 | $21 |
| G&A Expenses | $3 | $6 | $10 | $10 |
| SG&A Expenses | $3 | $6 | $11 | $10 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | -$2 | -$9 | -$4 |
| Operating Expenses | $6 | $8 | $20 | $27 |
| Operating Income | -$6 | -$8 | -$41 | -$26 |
| % Margin | -3,149.5% | -8,291.2% | – | – |
| Other Income/Exp. Net | $0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$6 | -$9 | -$41 | -$27 |
| Tax Expense | $0 | -$0 | $0 | $0 |
| Net Income | -$6 | -$8 | -$41 | -$27 |
| % Margin | -3,131.2% | -8,282.4% | – | – |
| EPS | -0.14 | -0.33 | -1.81 | -1.7 |
| % Growth | 57.6% | 81.8% | -6.5% | – |
| EPS Diluted | -0.14 | -0.33 | -1.81 | -1.7 |
| Weighted Avg Shares Out | 41 | 26 | 23 | 16 |
| Weighted Avg Shares Out Dil | 41 | 26 | 23 | 16 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $1 | $1 | $2 |
| EBITDA | -$6 | -$8 | -$40 | -$25 |
| % Margin | -3,057.5% | -7,610.8% | – | – |